drugset
drugset / Trial / NCT07617337

AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer

NCT07617337 ↗

Phase 1 Not yet recruiting 102 enrolled Chugai Pharmaceutical
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a first-in-human, Phase I, open-label, multicenter, multinational study, designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of AQUA07 when administered as single agent and in combination with lorlatinib in patients with ALK positive non-small cell lung cancer.

Timeline

Start
2026-07-31
Primary completion
2030-08-31
Completion
2030-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject AQUA07 Unknown — Oral
Background Lorlatinib Small molecule — Oral

Indications

non-small cell lung carcinoma